Arcutis announced positive Phase 2 INTEGUMENT-INFANT data for ZORYVE (roflumilast) 0.05% cream showing reduced signs and symptoms of atopic dermatitis in infants, supporting pediatric efficacy. If results are confirmed in larger trials and used in regulatory filings, this could expand ZORYVE's addressable market in pediatrics and improve commercial prospects. Expect a modest stock reaction (roughly 1–3%) on the news pending further detail and follow-up data.
Arcutis announced positive Phase 2 INTEGUMENT-INFANT data for ZORYVE (roflumilast) 0.05% cream showing reduced signs and symptoms of atopic dermatitis in infants, supporting pediatric efficacy. If results are confirmed in larger trials and used in regulatory filings, this could expand ZORYVE's addressable market in pediatrics and improve commercial prospects. Expect a modest stock reaction (roughly 1–3%) on the news pending further detail and follow-up data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
